Efficacy of enlicitide, an oral PCSK9 inhibitor, across baseline Lp(a) strata in an analysis of two phase 3 trials

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Novel lipid‑lowering therapies for residual risk Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology